Antioxidant effects of statins

被引:104
作者
Stoll, LL [1 ]
McCormick, ML
Denning, GM
Weintraub, NL
机构
[1] Univ Iowa, Dept Internal Med, Div Cardiovasc Dis, Iowa City, IA 52242 USA
[2] Univ Iowa, Div Infect Dis, Iowa City, IA 52242 USA
[3] Univ Iowa, Dept Radiol, Free Radical & Radiat Biol Program, Iowa City, IA 52242 USA
[4] Vet Affairs Med Ctr, Iowa City, IA 52242 USA
关键词
D O I
10.1358/dot.2004.40.12.872573
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Statins, a group of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are widely used in clinical practice for their efficacy in producing significant reductions in plasma cholesterol and LDL cholesterol and in reducing morbidity and mortality from cardiovascular disease. However, several large clinical trials have suggested that the cholesterol-lowering effects of statins may not completely account for the reduced incidence of cardiovascular disease seen in patients receiving statin therapy. A number of recent reports have shown that statins may also have important antiinflammatory effects, in addition to their effects on plasma lipids. Since inflammation is closely linked to the production of reactive oxygen species (ROS), the molecular basis of the observed antiinflammatory effects of statins may relate to their ability block the production and/or activity of ROS. In this review, we will discuss both the inhibition of ROS generation by statins, through interference with NAD(P)H oxidase expression and activity, and the actions of statins that serve to blunt the damaging effects of these radicals, including effects on antioxidant enzymes, lipid peroxidation, LDL cholesterol oxidation and nitric oxide synthase. These antioxidant effects of statins likely contribute to their clinical efficacy in treating cardiovascular disease as well as other chronic conditions associated with increased oxidative stress in humans. (C) 2004 Prous Science. All rights reserved.
引用
收藏
页码:975 / 989
页数:15
相关论文
共 135 条
[1]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[2]  
Albertini R., 2002, Current Molecular Medicine (Hilversum), V2, P579, DOI 10.2174/1566524023362177
[3]   Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors [J].
Alfon, J ;
Guasch, JF ;
Berrozpe, M ;
Badimon, L .
ATHEROSCLEROSIS, 1999, 145 (02) :325-331
[4]   Statins, inflammation, and sepsis - Hypothesis [J].
Almog, Y .
CHEST, 2003, 124 (02) :740-743
[5]   Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS .
ATHEROSCLEROSIS, 1998, 138 (02) :271-280
[6]   NADPH oxidase: An update [J].
Babior, BM .
BLOOD, 1999, 93 (05) :1464-1476
[7]   EXOGENOUS COQ(10) PRESERVES PLASMA UBIQUINONE LEVELS IN PATIENTS TREATED WITH 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE INHIBITORS [J].
BARGOSSI, AM ;
BATTINO, M ;
GADDI, A ;
FIORELLA, PL ;
GROSSI, G ;
BAROZZI, G ;
DIGIULIO, R ;
DESCOVICH, G ;
SASSI, S ;
GENOVA, ML ;
LENAZ, G .
INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1994, 24 (03) :171-176
[8]   Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[9]   Non-lipid-related effects of statins [J].
Bellosta, S ;
Ferri, N ;
Bernini, F ;
Paoletti, R ;
Corsini, A .
ANNALS OF MEDICINE, 2000, 32 (03) :164-176
[10]  
Beltowski J, 2002, POL J PHARMACOL, V54, P661